Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Puma Biotechnology Tumbled Today

By Maxx Chatsko - Oct 8, 2019 at 11:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst downgrade and a departing executive make for a bad day.

What happened

Shares of Puma Biotechnology (PBYI -2.45%) fell as much as 20.2% after the company disclosed through a filing with the Securities and Exchange Commission that Chief Commercial Officer Steven Lo will resign on Oct. 18 to become the CEO of an emerging pharmaceutical company. However, a departing executive isn't the real reason shares are tumbling. 

In an unrelated move, Goldman Sachs analyst Paul Choi downgraded Puma Biotechnology stock from neutral to sell, changed the price target from $24 to $8 per share, cut his 2025 sales estimate by 25%, and reminded investors that Seattle Genetics (SGEN 0.16%) has a drug candidate that might compete well against Puma's Nerlynx, according to

As of 11:08 a.m. EDT, Puma Biotechnology stock had settled to a 17.4% loss.

A sad-looking scientist in a lab with his left hand on his forehead.

Image source: Getty Images.

So what

Puma Biotechnology hasn't been able to convince investors or Wall Street that Nerlynx can live up to its blockbuster potential. The drug product, prescribed for one year to individuals that have completed treatment for breast cancer, has faltered recently. A significant number of individuals have to discontinue treatment due to severe side effects, although that decision is a lot easier for doctors to make considering the drug's questionable value and high cost.

While Nerlynx has gradually earned supplemental approvals from regulators to expand its use, revenue growth has slowed significantly due to patient churn. Sales in the second quarter of 2019 grew only 6% from the year-ago period. Licensing revenue from international sales should begin to trickle in soon, and operating losses are beginning to shrink, but investors are concerned with the drug's future. Nerlynx is the only drug product or drug candidate owned by Puma Biotechnology.

Nerlynx has struggled to overcome its own inherent problems relating to tolerability, which Choi thinks could be further exposed by a drug candidate from Seattle Genetics. Tucatinib is being evaluated in the same settings as Nerlynx, has proven to have fewer side effects, and is expected to have new data from an important clinical trial before the end of 2019. Choi thinks better tolerability could allow tucatinib to grab more market share than Nerlynx even if it proves less effective, but the drug candidate has to earn marketing approval first.

Now what

It may be tempting to label Puma Biotechnology as a value stock, especially considering that the company's market cap now sits at just $325 million. On the one hand, the business could achieve sustainable operations with just a little more growth from Nerlynx. Choi's optimism for tucatinib from Seattle Genetics may be a bit premature and overblown. After all, many have questioned the value of Nerlynx based on its high cost and slight improvement to overall survival, so could a less effective drug really make a splash even if it has fewer side effects?

On the other hand, Nerlynx is clearly not living up to expectations. It should receive a boost from recent supplemental approvals and international expansion, but investors might be better off waiting to see another quarter or two of operating results before getting too carried away.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Seattle Genetics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seagen Inc. Stock Quote
Seagen Inc.
$170.79 (0.16%) $0.27
Puma Biotechnology, Inc. Stock Quote
Puma Biotechnology, Inc.
$3.19 (-2.45%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.